(Q41655720)

English

Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.

scientific article published on 16 June 2015

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26092818%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26092818%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

phase III clinical trial

0 references

multicenter clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26092818%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

13

object named as

Masakazu Toi

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26092818%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

author name string

Sara A Hurvitz

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26092818%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Zefei Jiang

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26092818%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Zhimin Shao

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26092818%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Max S Mano

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26092818%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Silvia P Neciosup

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26092818%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Ling-Min Tseng

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26092818%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Qingyuan Zhang

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26092818%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Kunwei Shen

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26092818%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Donggeng Liu

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26092818%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Lydia M Dreosti

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26092818%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Howard A Burris

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26092818%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Marc E Buyse

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26092818%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

David Cabaribere

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26092818%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Mary-Ann Lindsay

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26092818%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Shantha Rao

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26092818%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Lida Bubuteishvili Pacaud

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26092818%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Tetiana Taran

19

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26092818%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Dennis Slamon

20

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26092818%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

publication date

16 June 2015

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26092818%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26092818%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26092818%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26092818%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

816-829

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26092818%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Adjuvant trastuzumab in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900051-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900051-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900051-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900051-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Trastuzumab--mechanism of action and use in clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900051-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Resistance to Trastuzumab in Breast Cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900051-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Advances and future directions in the targeting of HER2-positive breast cancer: implications for the future.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900051-0

7 January 2021

based on heuristic

inferred from DOI database lookup

PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900051-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900051-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900051-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900051-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900051-0

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900051-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900051-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900051-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900051-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900051-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: an exploratory analysis of the TRYPHAENA study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900051-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900051-0

7 January 2021

based on heuristic

inferred from DOI database lookup

2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900051-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900051-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900051-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900051-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900051-0

7 January 2021

based on heuristic

inferred from DOI database lookup

AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900051-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900051-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900051-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900051-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900051-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Noninfectious pneumonitis with the use of mTOR inhibitors in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900051-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900051-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(15)00051-0

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26092818%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26092818%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41655720&oldid=1923801917"